Biomarker Enterprise to Attack DKD (BEAt-DKD)
Chronic Kidney Disease (CKD) affects around 10% of the world’s population. DKD is the most common form of CKD, and its prevalence is expected to continue to increase. There is still an unmet need to find new, non-invasive biomarkers that can facilitate the development of treatment for DKD. MRI has the potential to non-invasively assess functional and morphologic, including fibrotic, changes in the kidney that may improve diagnosis, prognosis and treatment monitoring in patients with DKD.
We are proud to be a partner of the BEAt DKD consortium. The goal of the project is to identify and validate biomarkers of disease progression and treatment responses, as this will support a better understanding of the disease as well as development of novel therapies.
Antaros Medical is contributing to the project by analysing and delivering imaging assessments of body composition, including endpoints from the liver, pancreas and visceral adipose tissue (VAT). These images are collected as part of the iBEAt study, a longitudinal 4-year observational study in more than 500 DKD patients.
The BEAt DKD project brings together 33 partners across academia, pharmaceutical and biotechnology companies, patient organisations, and small and medium-size enterprises (SMEs).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and JDRF.
Link to IMI website: https://www.imi.europa.eu/
Link to BEAt DKD website: https://www.beat-dkd.eu/project/
Link to IMI Project Factsheet: https://www.imi.europa.eu/projects-results/project-factsheets/beat-dkd
BEAt DKD consortium partners:
- Coordinator: Lund University
- Lead: Sanofi, Abbvie
- Partners: Antaros Medical, Astellas Pharma, Bayer, Boehringer Ingelheim, CHU Hopitaux de Boreaux, Eli Lilly & Company, Instituto di Ricerche Farmacologiche Mario Negri, JDRF, Lipotype, Medizinische Universitat Innsbruck, Medizinische Universitat Wien, Novo Nordisk, Swiss Institute of Bioinformatics, University of Bristol, Universita degli Studi de Bari Aldo Moro, University of Dundee, Universitatsklinikum Erlangen, University of Exeter, University of Eastern Finland, University of Helsinki, University of Hull, University of Leeds, University Medical Center Freiburg, University Medical Center Groningen (UMCG), University Medical Centre Hamburg-Eppendorf, University of Michigan, University of Oxford, Universitatsklinikum Regensburg, The University of Sheffield, University of Turku